AIG Hospitals Introduces PillBot to Advance Non-Invasive GI Diagnostics

PillBot, a capsule measuring 13mm by 30mm, is equipped with high-resolution cameras, sensors, and wireless connectivity. 

AIG Hospitals, in partnership with US-based innovator Endiatx, has unveiled PillBot, a robotic capsule endoscopy technology. This marks a transformative shift in gastrointestinal (GI) diagnostics in India. 

The device, a swallowable capsule equipped with advanced imaging and AI capabilities, offers a non-invasive alternative to traditional endoscopy, enhancing patient convenience and diagnostic precision.

“This cutting-edge technology represents a monumental leap forward in gastroenterology,” said Dr. D. Nageshwar Reddy, Chairman of AIG Hospitals.

“PillBot combines precision with patient convenience, offering a glimpse into the future of diagnostic care.”

The device was introduced during an event at AIG Hospitals' Gachibowli facility, attended by leading global experts, including Dr. Vivek Kumbhari from the Mayo Clinic and Dr. Alex Luebke, Co-founder of Endiatx.

How PillBot™ Works

The procedure is simple: patients fast and drink water before swallowing the capsule. Within 10 minutes, physicians can remotely explore the stomach, with the capsule naturally passing through the digestive system.

“The PillBot’s ability to provide high-resolution insights without invasive procedures marks a pivotal moment in patient care,” Dr. Reddy added.

PillBot, a capsule measuring 13mm by 30mm, is equipped with high-resolution cameras, sensors, and wireless connectivity. 

Once swallowed, it navigates the GI tract and transmits real-time, high-quality images to physicians, eliminating the need for sedation or invasive procedures.

AI Integration for Enhanced Diagnostics

PillBot integrates Artificial Intelligence (AI) to optimize its diagnostic potential.

AI-powered models analyze the captured data, enabling early detection of GI conditions and paving the way for personalized treatment plans.

“Our partnership with Endiatx extends beyond showcasing technology,” said Dr. Rakesh Kalapala, Director of the Centre for AI and Innovation at AIG Hospitals. 

“By contributing clinical data to Endiatx's research, we aim to enhance PillBot's efficiency and accelerate the development of AI-driven autonomous diagnostics.”

Research & Future Impact

Currently undergoing clinical trials in India, PillBot has yet to receive FDA approval. Despite being in the research phase, its potential impact is clear.

“This technology represents years of collaborative effort among engineers, clinicians, and scientists,” noted Dr. Kumbhari of the Mayo Clinic.

Dr. Alex Luebke shared the broader vision for PillBot, emphasizing its potential for widespread accessibility and preventive care strategies: “Our goal is to make PillBot not just a diagnostic tool but an essential component of proactive GI care.”

Dr. Reddy concluded by highlighting the cost-effectiveness of the technology: “While the current production cost is $100, mass production could reduce it to as low as $35, making it affordable and accessible across diverse healthcare settings.”

PillBot exemplifies the fusion of robotics and AI in healthcare, offering hope for a future where diagnostics are not only more efficient but also more patient-friendly.

Stay tuned for more such updates on Digital Health News.